Company Intelligence
Novartis is a global pharmaceutical company focused exclusively on innovative medicines following the 2023 spinoff of its generics division Sandoz. The company develops and commercializes therapies across five therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, solid tumors, and hematology. Novartis is a leader in cell and gene therapy through its Advanced Therapy Medicinal Products (ATMP) portfolio and operates one of the pharmaceutical industry's largest R&D organizations with over 200 projects in clinical development.
Pharmaceuticals & Life Sciences
Headquarters
Basel, Switzerland
Employees
~78,000
Revenue
$46.7B (FY2024)
Fiscal Year End
December 31
Founded
1996
Current leadership team based on public filings and announcements.
Vas Narasimhan
CEO
Harry Kirsch
CFO
Key events and changes that sales teams should know about.
Completed the Sandoz spinoff, becoming a pure-play innovative medicines company with higher margins, stronger growth trajectory, and more focused R&D investment in breakthrough therapies and advanced modalities.
2025-01
Expanded its cell and gene therapy pipeline with next-generation CAR-T treatments and gene-editing programs, positioning Novartis as a leader in curative therapies for cancer and rare genetic diseases.
2024-11
Q3 2024 net sales grew 10% at constant currencies to $12.8B, driven by strong performance from key growth brands Entresto (heart failure), Kisqali (breast cancer), and Cosentyx (immunology), with core operating income margin expanding to 40%.
2024-10
Scaled AI research partnerships across drug discovery, clinical trial design, and manufacturing optimization, including collaborations with Microsoft, Isomorphic Labs, and internal AI/ML teams to accelerate pipeline progression.
2024-08
Advanced radioligand therapy (RLT) capabilities following the Lutathera and Pluvicto launches, building a new therapeutic modality that targets cancer cells with precision-guided radioactive molecules.
2024-05
The Sandoz spinoff makes Novartis a purer, more focused pharmaceutical company comparable to its Basel neighbor Roche. This focus means Novartis can deploy its entire R&D budget (roughly $10 billion annually) on innovative medicines rather than splitting resources with a generics business. For vendors selling technology or services to pharma, this creates a customer with a clear mandate: accelerate innovation, expand margins, and win in the most competitive therapeutic categories. Procurement priorities are sharply focused on tools that drive pipeline productivity.
Novartis's leadership in cell and gene therapy and radioligand therapy represents the frontier of pharmaceutical innovation. These advanced modalities require entirely different manufacturing, supply chain, and commercial capabilities compared to traditional small-molecule drugs. This creates demand for specialized technology solutions -- from chain-of-custody tracking for personalized cell therapies to radiopharmaceutical logistics platforms. Vendors with expertise in these areas will find Novartis a significant buyer.
Novartis's December 31 fiscal year end aligns with the calendar year, and the company reports in US dollars (unlike neighbor Roche, which reports in Swiss francs). Being headquartered in Basel, Novartis follows European procurement practices with multi-stakeholder decision-making and longer evaluation cycles. The company's global operations span over 140 countries, so regional procurement teams often have significant autonomy within framework agreements set by global category managers.
Key competitors based on market analysis and public filings.
Novartis's fiscal year ends on December 31, following the standard calendar year. The company reports full-year results in late January, with quarterly updates in April, July, and October. Unlike Roche, Novartis reports in US dollars despite being headquartered in Switzerland.
Novartis generates approximately $46.7 billion in annual revenue as of FY2024, growing at roughly 10% at constant currencies. Key growth drivers include Entresto (heart failure), Kisqali (breast cancer), Cosentyx (immunology), and Pluvicto (radioligand therapy for prostate cancer).
Novartis is headquartered in Basel, Switzerland, on its landmark Novartis Campus designed by renowned architects. The company was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two historic Swiss pharmaceutical and chemical companies.
Sandoz was spun off from Novartis as an independent publicly traded company in October 2023. Sandoz is now the world's largest standalone generics and biosimilars company. The separation allows Novartis to focus entirely on innovative medicines while Sandoz operates independently with its own strategy and capital allocation.
Novartis employs approximately 78,000 people globally following the Sandoz separation. The workforce spans drug discovery, clinical development, manufacturing, and commercial operations across more than 140 countries, with major R&D hubs in Basel, Cambridge (Massachusetts), and Shanghai.
See leadership changes, strategic initiatives, earnings insights, and buying signals for Novartis — updated continuously.
